PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq:PDSB) (“PDS Biotech” or “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced today that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company’s new Chief Financial Officer, to purchase a total of 200,000 shares of the Company’s common stock as a material inducement to Mr. Boesgaard’s employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech’s 2019 Inducement Plan, as amended, which was adopted on June 17, 2019 and provides for the granting of equity awards to new employees of PDS Biotech.

Read more at globenewswire.com